Detalhe da pesquisa
1.
Effect of pentaerythritol tetranitrate (PETN) on the development of fetal growth restriction in pregnancies with impaired uteroplacental perfusion at midgestation-a randomized trial.
Am J Obstet Gynecol
; 228(1): 84.e1-84.e12, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35931132
2.
Comparison of the Soluble fms-Like Tyrosine Kinase 1/Placental Growth Factor Ratio Alone versus a Multi-Marker Regression Model for the Prediction of Preeclampsia-Related Adverse Outcomes after 34 Weeks of Gestation.
Fetal Diagn Ther
; 50(3): 215-224, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809755
3.
Pentaerythrityl tetranitrate improves the outcome of children born to mothers with compromised uterine perfusion-12-months follow-up and safety data of the double-blind randomized PETN trial.
Am J Obstet Gynecol MFM
; 6(4): 101332, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460823
4.
The CHANGED Score-A New Tool for the Prediction of Insulin Dependency in Gestational Diabetes.
J Clin Med
; 12(22)2023 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38002781
5.
Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction.
Pregnancy Hypertens
; 28: 149-155, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35453103